Orphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,010 DKK | -7.76% | +2.20% | -24.06% |
Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
1st Jan change | Capi. | |
---|---|---|
-24.06% | 5.15M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ORPHA Stock
- News Orphazyme A/S
- Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO